| ID | Title | Body | Facebook Description | Facebook image | Facebook Title | Facebook Video | Twitter Description | Twitter Image | Twitter Title | Meta tags |
|---|---|---|---|---|---|---|---|---|---|---|
| 210 | Conduits, The Institutes for Translational Sciences at the Icahn School of Medicine at Mount Sinai | New York, New York Principal Investigator Rosalind J. Wright, M.D., M.P.H., Icahn School of Medicine at Mount Sinai Website The goal of Conduits, the Institutes for Translational Sciences at the Icahn School of Medicine at Mount Sinai is to establish a research paradigm that will: Facilitate bench-to-bedside translation of cutting-edge research, Create an academic home for clinical and translational investigators, and Supply the governance and resources needed to allow clinical investigators to benefit from Mount Sinai's Translational Research Institutes and potential collaborators. To accomplish this, Conduits will redesign its research infrastructure to integrate research functions across departments, enhance and promote interactions between basic scientists and clinical investigators, and streamline administrative procedures for new clinical trials and dissemination of results. It will establish a Translational Discoveries Program to provide consultation, oversight and facilities for clinical and translational research. Conduits also will engage the community and its affiliates to translate health benefits to the public. And it will develop methodologies to improve trial design and reduce participant burden. To recruit and retain clinical and translational researchers, Conduits will train and support new investigators in a multidisciplinary, doctoral degree-granting program in clinical and translational research. It also will develop a recruitment program and enhance career development. An innovative Experimental Therapeutics & Technologies Program will identify and develop novel clinical and translational research projects and connect basic and clinical researchers, caregivers and laboratories through an integrated network of information. Conduits will create an effective, efficient and centralized research administrative structure. It will foster and reward interdisciplinary collaborations, educate and retain new clinical and translational investigators, and enable translation of basic scientific discoveries into clinical practice. Conduits also will deliver to its diverse community new therapies and an improved standard of care. | ||||||||
| 209 | Chemistry Technology Projects | Damien Deveau, Ph.D., works in the NCATS chemistry laboratory. (Daniel Soñé Photo) NCATS supports innovative research in biology and spurs advances in drug discovery by investing in the development of new chemistry technologies. Center experts in this discipline work on varied projects that address fundamental problems in molecular biology and the drug discovery process. NCATS supports chemical technologies ranging from novel small molecule library design to inventive bioanalytical techniques. Explore selected chemistry technology active projects and completed projects. | NCATS' chemistry technology experts work on varied projects for developing new chemistry technologies to address problems in molecular biology and the drug discovery process. | /sites/default/files/chemtech-about.jpg | Chemistry Technology Projects | NCATS' chemistry technology experts work on varied projects for developing new chemistry technologies to address problems in molecular biology and the drug discovery process. | /sites/default/files/chemtech-about.jpg | Chemistry Technology Projects | ||
| 208 | Colorado Clinical and Translational Sciences Institute | Aurora, Colorado Principal Investigator Ronald J. Sokol, M.D., University of Colorado Denver Website The Colorado Clinical and Translational Sciences Institute (CCTSI), created in 2008, includes the University of Colorado Denver, the University of Colorado Boulder, Colorado State University, six major hospitals and health care organizations, and local communities. CCTSI will: Expand this statewide academic home for clinical and translational research. Implement new clinical research management strategies to improve quality, safety, efficiency, cost-effectiveness and innovative team science as well as introduce new software systems and workflows. Centralize the delivery of resources, services and technologies. Incorporate key concepts of community engagement into the full spectrum of translational research. Increase the capacity of the translational research workforce through a broad curriculum of education, training and career development opportunities. A rigorous tracking, assessment and evaluation program with a formal quality and process improvement component will ensure the best use of resources while protecting the safety of research study participants. These programs will be centralized at the University of Colorado’s Anschutz Medical Campus, which is adjacent to participating schools, research laboratories, three hospitals and a biomedical corporate park. | ||||||||
| 207 | Clinical and Translational Science Institute at Children's National | Washington, District of Columbia Principal Investigator Lisa M. Guay-Woodford, M.D., Children's National Medical Center Website The Clinical and Translational Science Institute at Children's National (CTSI-CN) offers a unique set of resources in translating discovery to improved health. CTSI-CN provides highly integrated, cost-effective, investigator-focused resources designed to overcome research barriers, promote collaborative research and provide research training in the area of children's health. With an emphasis on health disparities and childhood antecedents to adult diseases, this center will build upon its pediatric research strengths in areas such as rare diseases, asthma and neurodevelopmental disabilities to collaborate with a national network of 1,200 community health centers. The specific objectives of CTSI-CN are to: Provide state-of-the-art, flexible resources required by clinical and translational researchers, Promote multidisciplinary clinical and translational research (CTR), Strengthen CTR education and training for diverse trainees at all stages of career development, Promote demographic diversity and address health disparities, Incorporate effective and sustained collaboration with community partners, Ensure research efficiency, and Establish bidirectional collaborations with the CTSA Program network. (CTSI-CN lends its unique perspective on pediatric health issues and urban health disparities to the already distinguished members of the CTSA Program network.) Some key features of CTSI-CN are to expand CTR education and training, making it available from high school through mid-career, encourage community-based research at diverse locations, and overcome gaps in innovative research methodologies to support research. | ||||||||
| 206 | Case Western Reserve University Clinical and Translational Science Collaborative | Cleveland, Ohio Principal InvestigatorMichael Konstan, M.D., Case Western Reserve University Website The Clinical and Translational Science Collaborative, based at Case Western Reserve University, includes three hospital affiliates of the School of Medicine, the Cleveland Clinic, University Hospitals and MetroHealth Medical Center. Together, these hospitals cover 90 percent of the medical care delivered in the seven-county area surrounding Cleveland, Ohio, offering a wealth of clinical research opportunities. In addition, excellent programs based in the Frances Payne Bolton School of Nursing and the School of Dental Medicine, as well as those in the School of Medicine and its hospital affiliates reach into the community at many sites, some of which have become study sites in the CTSC. Together with the strong biomedical cores, the reach of these programs affords great opportunity for collaborative clinical research. | ||||||||
| 205 | Boston University Clinical and Translational Science Institute | Boston, Massachusetts Principal Investigator David M. Center, M.D., Boston University Website The Boston University Clinical and Translational Science Institute (BU CTSI) will integrate, connect and expand research and programs across traditional academic departments and schools. The institute will act as a bridge between disciplines to facilitate interactions by incorporating multiple key programs that support the university-wide commitment to a home for translational research. The CTSA Program grant will allow the institute to build on existing strengths to create an environment linking faculty members, trainees and university programs to speed the translation of innovations in medical science to improve maintenance of health and diagnosis and treatment of diseases and share these innovations with other university-based CTSA Program hubs. The BU CTSI environment also will support the bidirectional development and translation of ideas that begin in the clinic to the BU scientific community and back to identify new ways to improve health and delivery of health care services. Moreover, the institute will significantly enhance existing partnerships with Boston's community health centers, transforming the conduct of clinical and translational research by infusing it with community-based perspectives and needs. | ||||||||
| 204 | Work with Chemistry Technology | Discover how to partner with our chemistry technology experts to advance translational research.We work to develop innovative chemical tools is collaborative by nature. We encourage new partnership opportunities, including disease-specific projects with patient support groups and disease foundations. How to CollaborateResearchers who have a specific chemistry technology need and want to work with our chemistry technology experts can follow the steps outlined below.Submit a RequestSend an email to Jennifer Kouznetsova with the following details:• A summary of the idea or vision• Research goals• Project needs• Level or area of chemistry knowledgeProject SelectionNCATS staff will assess the idea and try to match the researcher with the appropriate expert.Project Initiation, Conduct and ClosingOnce we determine if the research goals and needs align with those of the Center, a formal collaboration agreement may be formed, if necessary, and the project may begin. | ||||||||
| 203 | Block Institute for Clinical and Translational Research at Einstein and Montefiore | Bronx, New York Principal InvestigatorHarry Shamoon, M.D., Albert Einstein College of Medicine Website The Block Institute for Clinical and Translational Research at Einstein and Montefiore (ICTR) was created in 2007 as the formal research partnership between the Albert Einstein College of Medicine and the Montefiore Medical Center. As both institutions adapt to the transformations in health care and biomedical research, ICTR provides a home where natural collaborations can occur and innovations can flourish. The broad scope of the ICTR mission — from translational bench sciences to community health — is consistent with human health being a result of many interdependent factors, including individual, genetic and societal factors. ICTR’s overarching goals are to: Provide integrated resources to support and speed planning, implementation and completion of investigation across the entire spectrum of research. Enhance quality, safety and efficiency of clinical and translational research for all diseases and conditions. Develop new innovations that advance clinical and translational sciences. Facilitate the training and career development of a robust translational research workforce. To accomplish these goals, ICTR provides support for the full range of translational sciences, interoperable biomedical informatics, therapeutics development, child health research, and patient- and population-centered outcomes research. ICTR has expanded its research cores for clinical trials and regulatory support; clinical investigation services; biostatistics, epidemiology and research design; biomarker and analytic research; biospecimen banking; community engagement consultation; research informatics; and project management and acceleration. The Research Training, Education and Career Development program provides an educational environment that serves learners at all levels in all types of clinical and translational research, focusing on core competencies and innovative mentoring approaches. | ||||||||
| 202 | Atlanta Clinical & Translational Science Institute | Atlanta, Georgia Principal Investigator David S. Stephens, M.D., Emory University Website The Atlanta Clinical & Translational Science Institute (ACTSI) is led by Emory University, along with partners Morehouse School of Medicine, Georgia Institute of Technology (Georgia Tech) and Children's Healthcare of Atlanta. These institutions hold existing partnerships in health care, education and cutting-edge, interdisciplinary research that is propelled by ACTSI. The established partnerships and diverse faculty enable ACTSI to combine strong clinical, translational, training and basic discovery programs at Emory with the health disparities, training and community outreach focus of Morehouse School of Medicine, together with the engineering and bioinformatics achievements of Georgia Tech and the excellence in pediatrics of Children's Healthcare of Atlanta. Collaborations with the private, nonprofit Georgia Bio organization and the Georgia Research Alliance, the state-sponsored academic-industry partnership, create additional synergies that foster and accelerate development and application of new and emerging technologies. Finally, ACTSI creates dynamic community, public health, informatics and population studies programs through partnerships and collaborations with Emory’s Winship Cancer Institute, the Centers for Disease Control and Prevention, and the Atlanta Veterans Affairs Medical Center. | ||||||||
| 201 | Chemistry Technology Scientific Capabilities | NCATS scientist Patrick Sutter in the Chemistry Technology lab. (Daniel Soñé Photo)We pursue and develop areas of focus, including new bioinformatics techniques, ‘omics integration strategies and novel strategies to probe pharmacology-to-phenotype assessments.Core and Novel CompetenciesView the core and novel competencies that NCATS offers in automation, compound management, analytical chemistry and informatics.Synthetic and Medicinal ChemistrySynthetic and medicinal chemistry are a key research focus for the program.Advancement of Candidate Small Molecules and Drug RepositioningThis area involves development of bioactive small molecules through the preclinical pipeline, including pharmacokinetic/pharmacodynamics assessments; CMC (chemistry, manufacturing and control)–related activities, such as salt and crystal form determination; toxicity assessment of candidate agents; and repositioning of approved and investigational drugs.Library Design and ImplementationNCATS staff contribute to the design and implementation of mechanism interrogation plate (MIPe) libraries of pharmacologically defined small molecules with relevance to cancer, neurology, infectious diseases and stem cell biology.Phenotypic and Matrix ScreeningChemistry technology experts routinely develop and conduct phenotypic screens on MIPe libraries to determine mechanism-based relationships between phenotype and pharmacology. The matrix combination screening platform allows assessment of mechanistically related combination outcomes for basic and translational studies.-Omics/Phenotype/Pharmacology RelationshipsSpecified outcomes from phenotypic and matrix screening are analyzed based on the ‘omics background (RNA-Seq, phosphoproteome and metabolome) to gain contextual understanding of the phenotypic outcomes from key pharmacologies.Deconstructed PolypharmacologiesNCATS experts conduct analysis of the polypharmacology of specified agents to define the key target elements that give rise to a phenotypic outcome. These studies involve several techniques, including RNAi sensitization and in situ profiling technologies. Staff also redesign agents (often approved or investigational drugs) to home in on the polypharmacology and achieve an alternate profile. |
Last updated on